We have soon capacity for new co-laboration opportunities
We can support your drug development, discovery, in vitro and in vivo research, CRO contacts, support regulatory submission, people management,
First indication of PBA-0405 activity in patient settings
Pure Biologics released first biomarker data obtained in Phase O clinical study in Head and Neck patients receiving intra-tumoral injection
PBA-0111 received "Study may proceed" letter from FDA
Pure Biologics took another significant step forward by receiving a "study may proceed" letter from the US Food
First patient dosed with PBA-0405
Pure Biologics announced on July 15, 2024 the dosing of the first patient was with the candidate PBA-0405 in a
Coming more soon
This is Zermatt Consulting, a brand new site that's just getting started. Things will be up and running
PBA-0405 receives FDA "study may proceed"
We are proud to announce that Zermatt Consulting has played a significant role in Pure Biologics approval receival from the
Warm holiday wishes from Zermatt Consulting!
The year 2023 has been very busy and productive. Zermatt consulting was part of an exiting journey from drug discovery,
